

Highlights of This Issue 6953

SPECIAL FEATURES

CCR Translations

- 6955 | **MAGE: The Spell Is Broken**
Katayoun Rezvani
See article p. 7058

CCR Drug Updates

- 6958 | **Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma**
Evan J. Lipson and Charles G. Drake

Molecular Pathways

- 6963 | **Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells**
Nicola Giuliani and Irma Airoidi

Perspective

- 6971 | **DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies**
Graham A. Colditz and John Crowley

Reviews

- 6973 | **DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target**
Shadia Jalal, Jennifer N. Earley, and John J. Turchi
- 6985 | **Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives**
Jessica Godin-Ethier, Laïla-Aïcha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

HUMAN CANCER BIOLOGY

- 6992 | **Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I**
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsvankin, Marci Klaassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri
- 7003 | **Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB-NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome**
Yoshitsugu Mitani, Pulivarthi H. Rao, P. Andrew Futreal, Dianna B. Roberts, Philip J. Stephens, Yi-Jue Zhao, Li Zhang, Mutsumi Mitani, Randal S. Weber, Scott M. Lippman, Carlos Cautin, and Adel K. El-Naggar
- 7015 | **Mast Cells in Tumor Microenvironment Promotes the *In Vivo* Growth of Pancreatic Ductal Adenocarcinoma**
David Z. Chang, Ying Ma, Baoan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yong-jun Liu, Craig D. Logsdon, and Patrick Hwu
- 7024 | **Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis**
Aditi Bhattacharya, Ritu Roy, Antoine M. Snijders, Gregory Hamilton, Jesse Paquette, Taku Tokuyasu, Henrik Bengtsson, Richard C. K. Jordan, Adam B. Olshen, Daniel Pinkel, Brian L. Schmidt, and Donna G. Albertson
- 7035 | **Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium**
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu

CANCER THERAPY: PRECLINICAL

- 7047 **Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy**
Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu
- 7058 **Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4**
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard
See commentary p. 6955
- 7067 **Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells**
Andreas Höglund, Lisa M. Nilsson, Somsundar Veppil Muralidharan, Lisa A. Hasvold, Philip Merta, Martina Rudelius, Viktoriya Nikolova, Ulrich Keller, and Jonas A. Nilsson
- 7080 **Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies**
Hwa Jin Lee, Brian A. Wall, Janet Wangari-Talbot, Seung-Shick Shin, Stephen Rosenberg, Joseph L-K. Chan, Jin Namkoong, James S. Goydos, and Suzie Chen
- 7093 **Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma**
Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yves A. DeClerck, and C. Patrick Reynolds
- 7105 **Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5**
Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jianing Chen, Fengxi Su, Yan Zhang, and Erwei Song
- 7116 **Novel Phosphoinositide 3-kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells *In Vitro* and *In Vivo***
Kwang-Yu Chang, Shan-Yin Tsai, Ching-Ming Wu, Chia-Jui Yen, Bin-Fay Chuang, and Jang-Yang Chang

7127

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton, and Peggy A. Scherle

IMAGING, DIAGNOSIS, PROGNOSIS

7139

Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival

Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutter, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

7148

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Martin J. van den Bent, Lonkeke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevsmit, and Pim J. French

CANCER THERAPY: CLINICAL

7156

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquin Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom, and James L. Gulley

7174 | **GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy**

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohei Edamura, Ken-ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

7194 | **Relationship between Quantitative *GRB7* RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer**

Joseph A. Sparano, Lori J. Goldstein, Barrett H. Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L. Baehner, Roberto Bugarini, Steve Rowley, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, Paraic A. Kenny, George W. Sledge, Jr, and Robert Gray


PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

7183 | ***Cytokeratin-19* and *Mammaglobin* Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437**

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.



Clinical Cancer Research

17 (22)

Clin Cancer Res 2011;17:6953-7203.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/22>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/22>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.